Biotech Values

[xrymd]

I've spoken with a small handful of docs unconnected to pymx and all said the opposite of you on both thrombin and Protamine.

FWIW I spoke to the chief of cardiovascular surgery (in the MD's cafeteria) and also to cardiac anesthesia. Both couldn't even remember a significant protamine reaction. They said protamine is simple to use so they doubted it would be replaced. There may be a statistical benefit to this new drug which may not be clinically relevant. Time will tell.

PYMX may be a good for a trade but unless they have some other "great" product long term sucess to would seem to be doubtful. Building a sales force to replace a dirt cheap drug doesn't seem to promising.